Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

New Study Extends Application Range of GILUPI CellCollector® Towards Quantitative Analysis of Gene Expression in Circulating Tumor Cells

publication date: Mar 19, 2018
author/source: GILUPI

New-Study-Extends-Application-Range-GILUPI-CellCollector-Towards-Quantitative-Analysis-Gene-Expression-Circulating-Tumor-CellsGILUPI announces the publication of a peer reviewed study about a new and promising mRNA-based assay that allows detection and quantification of clinically relevant prostate and pancreas cancer markers in circulating tumor cells (CTCs).

CTCs are a surrogate marker for cancer progression and response to therapy. CTCs indicate tumor cell spreading and are a prerequisite for the development of metastasis. Detection and characterization of these rare cells could provide a powerful approach for early disease diagnosis as well as disease monitoring. The GILUPI CellCollector® offers medical personnel at any point-of-care with the unique opportunity to enrich these CTCs in vivo.

In this peer reviewed study, El-Heliebi from the Medical University of Graz and his coworkers combine the enumeration and expression analysis of CTCs by developing an in situ padlock probe assay. This method enables the quantitative analysis of mRNA expression for therapy relevant cancer markers. For this study, the GILUPI CellCollector® was applied to patients with prostate and pancreatic cancer and subsequent CTC enumeration and detection of mRNA transcripts were conducted by fluorescence microscopy.

In summary, CTCs were detected in 62% of prostate cancer and 47% of pancreatic cancer patients and therapy relevant cancer markers (e.g. AR-V7 transcripts or KRAS mutations) were identified in the majority of those cells. This advanced approach will improve the predictive and prognostic value of CTC analysis in clinical practice and therefore lead to further advances in cancer research and patient care.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.